A projected impact and cost-effectiveness analysis estimated reductions in colorectal cancer (CRC) incidence and mortality with novel blood-based and stool-based CRC screening tests versus established alternatives.
A projected impact and cost-effectiveness analysis estimated reductions in colorectal cancer (CRC) incidence and mortality with novel blood-based and stool-based CRC screening tests versus established alternatives.